Clinical trials: Schizophrenia Patients
Dental Diseases, Schizophrenia
Oral Status of Patients Suffering From SCHIZophrenia Followed at Charles Perrens Hospital
The aim of the study is to describe the oral health status of patients suffering from schizophrenia and schizoaffective disorders in a psychiatric institute in France.
- Trial name
- BUCCOSCHIZ (NCT04191200)
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Centre Hospitalier Charles Perrens, Bordeaux
Schizophrenia
Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia
This is a pilot study of pregnenolone as an augmentation treatment for schizophrenia. The goal of this placebo-controlled study is to provide preliminary efficacy data for potential pregnenolone effects on cognitive symptoms and…
- Trial name
- NCT00560937
- Testing
- Pregnenolone
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Durham VA Medical Center
Parkinson's Disease Psychosis
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
- Trial name
- NCT00477672
- Testing
- Pimavanserin tartrate (ACP-103)
- Where
- 78 sites in United States, Bulgaria and 5 more
- Volunteers
- 298 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia
Staccato Loxapine in Agitation (Proof of Concept)
The purpose of this study is to assess efficacy and safety of Staccato Loxapine in the treatment of acute agitation in schizophrenic patients.
- Trial name
- NCT00369577
- Testing
- Inhaled Loxapine 5 mg, Inhaled Loxapine 10 mg
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- Alexza Pharmaceuticals, Inc.
Psychotic Disorder
The Effectiveness of Forest Therapy on Psychotic Patients: Focusing on Changes in Inflammatory Pathways and The Psychotic Condition of Patients
General Formulation Are there any changes in the inflammatory pathway and psychotic conditions in patients given Forest Therapy compared to conventional psychotic disorder therapy? Specific Are there any differences in the levels…
- Trial name
- FT (NCT07436481)
- Testing
- Forest Therapy
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- Natalia Dewi Wardani, MD
Schizophrenia
Anti-Inflammatory Challenge in Schizophrenia
This study aims to illuminate the biological underpinnings of negative symptoms in schizophrenia-particularly motivational impairments-by probing the link between systemic inflammation and neural activity in reward-related brain…
- Trial name
- NCT05823532
- Testing
- Infliximab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Emory University
Schizophrenia Patients
Effect of Ashwagandha as Adjunct Therapy on BDNF and Cognitive Function in Schizophrenia Patients
This study aims to evaluate the effectiveness of Ashwagandha (Withania somnifera) as an adjunctive therapy in improving serum brain-derived neurotrophic factor (BDNF) levels and cognitive function in patients with schizophrenia…
- Trial name
- ASH-BDNF (NCT07541157)
- Testing
- Risperidone 4mg/day, Ashwagandha
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- Hasanuddin University
Psychomotor Agitation, Schizophrenia
A Study of Staccato Loxapine (ADASUVE®) for Inhalation
Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in schizophrenic or bipolar disorder patients.
- Conditions
- Psychomotor Agitation, Schizophrenia, Bipolar Disorder
- Trial name
- NCT04148963
- Testing
- Inhaled loxapine
- Volunteers
- 150 people
- Sponsor
- Lee's Pharmaceutical Limited
Tobacco Dependence, Schizophrenia
The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in Schizophrenia
Cigarette smoking represents a major health problem for patients suffering from schizophrenia. Compared to the general population, schizophrenic patients are significantly more likely to be addicted to nicotine.
- Trial name
- PSIAARP (NCT00495352)
- Testing
- Hihg-doseNRT, Low-dose NRT, bupropion
- Where
- Taiwan
- Volunteers
- 360 people
- Sponsor
- Yu-Li Hospital
Schizophrenia
A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
The objective of this study is to investigate the safety and efficacy of aripiprazole (initial dose 2 mg/day, maintenance dose 6-24 mg/day, maximum dose 30 mg/day) orally administered over a period of 52 weeks in subjects who…
- Trial name
- NCT01942148
- Testing
- Aripiprazole
- Where
- 8 sites in Japan
- Volunteers
- 68 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia, Cognition
Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia
The objective of this study is to explore the neurocognitive efficacy of Sertindole versus comparator in patients with schizophrenia using the MCCB.
- Trial name
- NCT00654706
- Testing
- Sertindole, Quetiapine
- Where
- 26 sites in United States
- Volunteers
- 264 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients
An inpatient/outpatient study to see if LY2140023 is better than placebo in acutely ill patients with schizophrenia.
- Trial name
- NCT01086748
- Testing
- Risperidone, LY2140023
- Where
- 28 sites in United States, Croatia and 1 more
- Volunteers
- 1,134 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia Spectrum and Other Psychotic Disorders
Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial
The aim of this study is to explore new safe effective psychotherapeutic interventions for schizophrenia through assessing the efficacy and acceptability of complementary "Insight Enhancement Program" (IEP) and "Metacognitive…
- Trial name
- NCT03955549
- Testing
- Insight Enhancement Program (IEP), Metacognitive Training for Psychosis (MCT), Treatment As Usual (TAU)
- Where
- Egypt
- Volunteers
- 99 people
- Sponsor
- Agiad Psychiatry Hospital
Emotional Dysfunction, Psychosis
Application of UP for Transdiagnostic Treatment of Emotional Disorders for UHR for Psychosis Patients
The principal aim of the study is to assess the efficacy of the Unified Protocol (UP) for the treatment of the comorbid symptomatology of patients with Ultra High Risk (UHR) for psychosis.
- Trial name
- NCT04929938
- Testing
- Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
- Where
- 2 sites in Spain
- Volunteers
- 42 people
- Sponsor
- Fundació Sant Joan de Déu
Schizophrenia, Schizotypal and Delusional Disorders
The Efficacy of Using a Smartphone App to Support Shared Decision Making in People With a Diagnosis of Schizophrenia
This study investigates the effects of using a smartphone app to support shared decision making (SDM) for people with schizophrenia-spectrum disorders in an outpatient treatment setting.
- Trial name
- NCT03554655
- Testing
- Momentum app
- Where
- 7 sites in Denmark
- Volunteers
- 194 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Healthy
Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia Patients
Randomized, inpatient, ascending multiple dose study given to subjects with schizophrenia and schizoaffective disorder to assess safety and tolerability.
- Trial name
- NCT00581243
- Testing
- SLV-313 SR
- Volunteers
- 32 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia, Metabolic Syndrome
Association of Multiple Genetic Polymorphisms With Clozapine-Associated Metabolic Change in Schizophrenia
We are going to investigate the association of multiple genetic polymorphisms with the metabolic side effects in patients with schizophrenia taking clozapine.
- Conditions
- Schizophrenia, Metabolic Syndrome, Genetic Polymorphism
- Trial name
- NCT00717509
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Seoul National Hospital
Schizophrenia, Schizoaffective Disorder
Clinical Trial of AVL-3288 in Schizophrenia Patients
Single-center, outpatient, randomized, double-blind, placebo-controlled, 3-treatment-phase, cross-over study to evaluate the safety, tolerability and efficacy of two oral doses of AVL-3288 each compared to placebo, in patients…
- Trial name
- NCT02978599
- Testing
- AVL-3288
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- New York State Psychiatric Institute
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of two dosages of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute episode of schizoaffective disorder.
- Trial name
- NCT00397033
- Testing
- Paliperidone ER
- Volunteers
- 316 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizo Affective Disorder
Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)
To characterize the real-life clinical use of AOM in a hospitalized patient population with schizophrenia, schizoaffective disorder or BP1 requiring LAI therapy and evaluate its short-term effectiveness associated with its…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
- Trial name
- INITIATE (NCT04907279)
- Testing
- Aripiprazole Once-Monthly (AOM)
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Otsuka Canada Pharmaceutical Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.